Lincluden Management Ltd. Has $10.53 Million Stake in Pfizer Inc. (NYSE:PFE)

Lincluden Management Ltd. boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 415,454 shares of the biopharmaceutical company's stock after purchasing an additional 29,617 shares during the period. Pfizer makes up 1.3% of Lincluden Management Ltd.'s portfolio, making the stock its 19th biggest position. Lincluden Management Ltd.'s holdings in Pfizer were worth $10,528,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in PFE. Clarity Asset Management Inc. acquired a new position in Pfizer during the 4th quarter valued at approximately $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the period. North Capital Inc. acquired a new position in Pfizer during the 1st quarter valued at approximately $28,000. Bernard Wealth Management Corp. acquired a new position in Pfizer during the 4th quarter valued at approximately $30,000. Finally, Horizon Financial Services LLC acquired a new position in Pfizer during the 1st quarter valued at approximately $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on PFE shares. BMO Capital Markets lowered their target price on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Jefferies Financial Group boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Finally, Wolfe Research boosted their price target on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and an average target price of $28.55.

Pfizer Stock Up 0.1%

Shares of NYSE PFE traded up $0.01 during trading hours on Thursday, hitting $25.37. The company had a trading volume of 25,643,723 shares, compared to its average volume of 38,513,248. The stock has a market capitalization of $144.25 billion, a P/E ratio of 18.39, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The firm's 50 day moving average is $24.26 and its 200-day moving average is $24.70.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.82 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.78%. Pfizer's dividend payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.